Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé
Xavier
X
Department of Uro-Neurology, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, and Medical Research Council (MRC) Centre for Transplantation, King's College London, London, UK. gamexavier@gmail.com
Khan
Shahid
S
Panicker
Jalesh N
JN
Kalsi
Vinay
V
Dalton
Catherine
C
Elneil
Sohier
S
Hamid
Rizwan
R
Dasgupta
Prokar
P
Fowler
Clare J
CJ
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D017060:Patient Satisfaction; D011788:Quality of Life; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D014563:Urodynamics
D019274:Botulinum Toxins, Type A